Theolytics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Science Park Edmund Halley Oxford Rd, Ox...Website
www.theolytics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Theolytics
Theolytics is a biotech company based in England that focuses on developing innovative oncolytic immunotherapy to combat solid tumors, particularly ovarian cancer. Their ADENOVO discovery platform utilizes viruses to create targeted therapies aimed at transforming patients' lives. The company combines expertise in virology, cancer biology, and immunology, partnering with top-tier investors and biopharmaceutical firms. Theolytics is committed to ensuring that everyone has access to groundbreaking therapies that promise lasting cures.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Theolytics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Theolytics recently announced quarterly report
Theolytics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Theolytics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Theolytics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Theolytics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Theolytics
Check out if Theolytics is spiking on competitors!
Click to see if Theolytics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Theolytics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Theolytics
Compare insights from companies similar to Theolytics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Theolytics
<$5M
11-50
Private
$6.8M
2017
N/A
Company Profile Activity
Activity Insights
Theolytics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Theolytics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Theolytics.
Theolytics financials insights
Gather financial insights about Theolytics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$6.8M
Theolytics Tech Stack
A closer look at the technologies used by Theolytics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Board of Directors
Left Company
Executive Move
Board of Directors
Theolytics News & Media
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
Oxford UK, May 28th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that its Phase 1 OCTOPOD-IP clinical trial of THEO-260, a novel oncolytic immunotherapy, given by intraperitoneal delivery in patients with Platinum-Resistant Ovarian Cancer will be presented as a ‘Trials in Progress’ poster at the 2026 American Society for Clinical Oncology (ASCO) World Congress. ASCO is taking place in Chicago, US from May 29 – June 2.Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
Oxford, UK, April 28, 2026 — Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
Oxford UK, March 4, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has been awarded, pending final negotiation, €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme. Horizon Europe 2025 is supporting high-impact clinical-stage projects aimed at improving patient outcomes and strengthening Europe’s scientific leadership. The grant to Theolytics willTheolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
Oxford UK, October 13, 2025. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, will present a Trials in Progress Poster at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany from October 17-21. Dr Margaret Duffy, CSO and Dr Matilde Saggese, CMO will be attending and will showcase the OCTOPOD-IV Phase I/IIa clinical trial of THEO-260, a novel oncolytic immunotherapy, given by intravenous delivery in pat
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Theolytics
Sign Up For FreeTo access detailed company insights
Theolytics is a biotech company based in England that focuses on developing innovative oncolytic immunotherapy to combat solid tumors, particularly ovarian cancer. Their ADENOVO discovery platform utilizes viruses to create targeted therapies aimed at transforming patients' lives. The company combines expertise in virology, cancer biology, and immu... Read More
